Manetti, Luca http://orcid.org/0000-0001-9911-5366
Deutschbein, Timo
Schopohl, Jochen
Yuen, Kevin C. J.
Roughton, Michael
Kriemler-Krahn, Ulrike
Tauchmanova, Libuse
Maamari, Ricardo
Giordano, Carla
Clinical trials referenced in this document:
Documents that mention this clinical trial
Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing’s disease: interim results from a long-term real-world evidence study
https://doi.org/10.1007/s11102-019-00984-6
Funding for this research was provided by:
Novartis Pharma AG
Article History
First Online: 22 August 2019
Compliance with ethical standards
:
: LM has served on Advisory Boards for Novartis. TD has received Honoraria and Research Grants from, served on Advisory Boards for, and acted as a Consultant for Novartis. KCJY has received Research Grants from Corcept Therapeutics and Novartis and served on Advisory Boards and acted as a Consultant for Corcept Therapeutics, Novartis, and Strongbridge. UKK, LT, MR, and RM are employees of Novartis. CG has received Research Grants from and served on Advisory Boards for Novartis. JS has received Lecture Fees from Novartis, Ipsen, and Pfizer and has served on Advisory Boards for Novartis and Ipsen.
: The study was conducted in accordance with the Declaration of Helsinki, and an independent Ethics Committee or Institutional Review Board for each study site approved the study protocol.
: All patients provided written informed consent to participate.